Description: This structure reveals the crystal structure of broadly neutralizing antibody AP33 bound to HCV E2 envelope glycoprotein antigenic site 412-423, establishing two distinct modes of antibody binding that can neutralize diverse HCV strains. The comparison with bnAb HCV1 shows different angles of approach and subtle β-hairpin conformational variations, providing critical structural insights for pan-genotypic HCV vaccine development.